Mediwound

MDWD · NASDAQ

$12.10−$0.60 (−4.72%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $12.70

Latest news

Press releaseSep 22, 7:00 AM ETGlobe Newswire
MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®
Press releaseSep 14, 7:00 AM ETGlobe Newswire
Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification
NewsAug 13, 9:43 AM ET
MediWound Q2 2026 Earnings Call: Complete Transcript
Press releaseAug 13, 7:00 AM ETGlobe Newswire
MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update
NewsMay 27, 9:33 AM ET
MediWound Reports Q1 2026 Results: Full Earnings Call Transcript
Press releaseMay 27, 7:00 AM ETGlobe Newswire
MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
Press releaseApr 13, 7:30 AM ETGlobe Newswire
Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement
Press releaseApr 7, 7:00 AM ETGlobe Newswire
MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
Press releaseApr 2, 3:26 PM ETGlobe Newswire
MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million
NewsMar 5, 7:02 AM ET
Insights into MediWound Q4 Earnings
Press releaseMar 5, 7:00 AM ETGlobe Newswire
MediWound Reports Fourth Quarter and Full Year 2025 Financial Results
NewsMar 5, 6:11 AM ET
Earnings Scheduled For March 5, 2026
NewsMar 4, 3:02 PM ET
What to Expect from MediWound's Earnings
NewsNov 21, 6:50 AM ETAvi Kapoor
Palo Alto To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Friday
Press releaseNov 20, 7:00 AM ETGlobe Newswire
MediWound Reports Third Quarter 2025 Financial Results and Provides Corporate Update
NewsNov 19, 11:03 AM ET
Examining the Future: MediWound's Earnings Outlook
NewsNov 25, 11:00 AM ET
Earnings Preview: MediWound
Press releaseJul 15, 7:32 AM ETPRNewswire
Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®

Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification

MediWound Q2 2026 Earnings Call: Complete Transcript

MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update

MediWound Reports Q1 2026 Results: Full Earnings Call Transcript

MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update

Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences

MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million

Insights into MediWound Q4 Earnings

MediWound Reports Fourth Quarter and Full Year 2025 Financial Results

Earnings Scheduled For March 5, 2026

What to Expect from MediWound's Earnings

Palo Alto To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Friday

MediWound Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Examining the Future: MediWound's Earnings Outlook

Earnings Preview: MediWound

Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd